|
US4234571A
(en)
*
|
1979-06-11 |
1980-11-18 |
Syntex (U.S.A.) Inc. |
Nonapeptide and decapeptide derivatives of luteinizing hormone releasing hormone
|
|
DE3411224A1
(de)
*
|
1984-03-27 |
1985-10-10 |
Hoechst Ag, 6230 Frankfurt |
Verfahren zur racematarmen herstellung von peptidzwischenprodukten der gonadorelin- und gonadorelinanaloga-synthese und neue zwischenprodukte bei diesem verfahren
|
|
US4760053A
(en)
*
|
1984-08-02 |
1988-07-26 |
Fernand Labrie |
Combination therapy for selected sex steroid dependent cancers
|
|
US4666885A
(en)
*
|
1985-02-08 |
1987-05-19 |
Fernand Labrie |
Combination therapy for treatment of female breast cancer
|
|
US4705778A
(en)
*
|
1985-10-22 |
1987-11-10 |
Sri International |
Orally active LHRH analogs
|
|
JPH0284272U
(no)
*
|
1988-12-20 |
1990-06-29 |
|
|
|
JP2672677B2
(ja)
*
|
1989-02-09 |
1997-11-05 |
タツプ・フアーマシユーテイカルズ・インコーポレイテツド |
Ｌｈｒｈ同族体
|
|
ES2077675T3
(es)
*
|
1989-03-10 |
1995-12-01 |
Endorecherche Inc |
Terapia combinada para el tratamiento de enfermedades sensibles a los estrogenos.
|
|
US5372996A
(en)
*
|
1989-03-10 |
1994-12-13 |
Endorecherche, Inc. |
Method of treatment of androgen-related diseases
|
|
ATE170753T1
(de)
*
|
1989-07-07 |
1998-09-15 |
Endorecherche Inc |
Androgenderivate zur hemming der aktivität der sexualsteroide
|
|
HUT60139A
(en)
*
|
1989-07-07 |
1992-08-28 |
Endorecherche Inc |
Process for producing pharmaceutical composition suitable for treating prostate cancer connected with androgen
|
|
GB9112859D0
(en)
*
|
1991-06-14 |
1991-07-31 |
Ici Plc |
Peptide process
|
|
KR950701527A
(ko)
*
|
1992-05-21 |
1995-04-28 |
라브리 페르낭 |
테스토스테론 5α 환원효소 활성 저해제(INHIBITORS OF TESTOSTERONE 5α-REDUCTASE ACTIVITY)
|
|
US6413536B1
(en)
|
1995-06-07 |
2002-07-02 |
Southern Biosystems, Inc. |
High viscosity liquid controlled delivery system and medical or surgical device
|
|
US7833543B2
(en)
*
|
1995-06-07 |
2010-11-16 |
Durect Corporation |
High viscosity liquid controlled delivery system and medical or surgical device
|
|
CA2192782C
(en)
|
1995-12-15 |
2008-10-14 |
Nobuyuki Takechi |
Production of microspheres
|
|
CA2192773C
(en)
|
1995-12-15 |
2008-09-23 |
Hiroaki Okada |
Production of sustained-release preparation for injection
|
|
US6448031B1
(en)
|
1996-06-13 |
2002-09-10 |
Itoham Foods Inc. |
Process for producing LH-RH derivatives
|
|
US20060025328A1
(en)
*
|
1997-05-28 |
2006-02-02 |
Burns Patrick J |
Compositions suitable for controlled release of the hormone GnRH and its analogs
|
|
US6051558A
(en)
*
|
1997-05-28 |
2000-04-18 |
Southern Biosystems, Inc. |
Compositions suitable for controlled release of the hormone GnRH and its analogs
|
|
US6242421B1
(en)
|
1997-11-06 |
2001-06-05 |
Richard Lloyd Bowen |
Methods for preventing and treating Alzheimer's disease
|
|
US6858598B1
(en)
|
1998-12-23 |
2005-02-22 |
G. D. Searle & Co. |
Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
|
|
US6833373B1
(en)
|
1998-12-23 |
2004-12-21 |
G.D. Searle & Co. |
Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
|
|
US20040265285A1
(en)
*
|
1999-04-15 |
2004-12-30 |
Monash University |
Normalization of defective T cell responsiveness through manipulation of thymic regeneration
|
|
US20040241842A1
(en)
*
|
1999-04-15 |
2004-12-02 |
Monash University |
Stimulation of thymus for vaccination development
|
|
US20040259803A1
(en)
*
|
1999-04-15 |
2004-12-23 |
Monash University |
Disease prevention by reactivation of the thymus
|
|
US20070274946A1
(en)
*
|
1999-04-15 |
2007-11-29 |
Norwood Immunoloty, Ltd. |
Tolerance to Graft Prior to Thymic Reactivation
|
|
AUPR074500A0
(en)
*
|
2000-10-13 |
2000-11-09 |
Monash University |
Treatment of t cell disorders
|
|
US20040258672A1
(en)
*
|
1999-04-15 |
2004-12-23 |
Monash University |
Graft acceptance through manipulation of thymic regeneration
|
|
US20050020524A1
(en)
*
|
1999-04-15 |
2005-01-27 |
Monash University |
Hematopoietic stem cell gene therapy
|
|
ES2154590B1
(es)
|
1999-05-20 |
2001-11-01 |
Lipotec Sa |
Procedimiento de sintesis de peptidos en fase solida
|
|
AR023940A1
(es)
|
2000-05-03 |
2002-09-04 |
Eriochem Sa |
Procedimiento para la produccion de microcapsulas de liberacion prolongada de peptidos solubles en agua
|
|
DE10032256C2
(de)
*
|
2000-07-03 |
2003-06-05 |
Infineon Technologies Ag |
Chip-ID-Register-Anordnung
|
|
US20060088512A1
(en)
*
|
2001-10-15 |
2006-04-27 |
Monash University |
Treatment of T cell disorders
|
|
ES2705016T3
(es)
|
2001-02-19 |
2019-03-21 |
Novartis Int Pharmaceutical Ag |
Derivado de rapamicina para el tratamiento de cáncer de pulmón
|
|
BR0209647A
(pt)
|
2001-05-16 |
2004-07-27 |
Novartis Ag |
Combinação que compreende n-{5-[4-(4-metil-piperazino-metil)-benzoilamido]-2-metil fenil}-4-(3-piridil)-2-pirimidina-amina e um agente quimioterapêutico
|
|
US20060287282A1
(en)
*
|
2001-06-25 |
2006-12-21 |
Steiner Mitchell S |
Compositions comprising a SARM ad GnRH agonist or a GnRH antagonist, and methods of use thereof
|
|
WO2003041739A1
(en)
|
2001-11-13 |
2003-05-22 |
Takeda Chemical Industries, Ltd. |
Anticaner agents
|
|
GB0128510D0
(en)
*
|
2001-11-28 |
2002-01-23 |
Novartis Ag |
Organic compounds
|
|
US20030144203A1
(en)
*
|
2001-12-19 |
2003-07-31 |
Voyager Pharmaceutical Corporation |
Methods for slowing senescence and treating and preventing diseases associated with senescence
|
|
GB0206215D0
(en)
|
2002-03-15 |
2002-05-01 |
Novartis Ag |
Organic compounds
|
|
NZ560662A
(en)
|
2002-05-16 |
2009-09-25 |
Novartis Ag |
Use of EDG receptor binding agents in cancer
|
|
US20040001889A1
(en)
|
2002-06-25 |
2004-01-01 |
Guohua Chen |
Short duration depot formulations
|
|
EP2959893A1
(en)
|
2002-12-13 |
2015-12-30 |
DURECT Corporation |
Oral drug delivery system comprising high viscosity liquid carrier materials
|
|
WO2005012256A1
(en)
|
2003-07-22 |
2005-02-10 |
Astex Therapeutics Limited |
3, 4-disubstituted 1h-pyrazole compounds and their use as cyclin dependent kinases (cdk) and glycogen synthase kinase-3 (gsk-3) modulators
|
|
GB0320806D0
(en)
*
|
2003-09-05 |
2003-10-08 |
Astrazeneca Ab |
Therapeutic treatment
|
|
US20080279812A1
(en)
*
|
2003-12-05 |
2008-11-13 |
Norwood Immunology, Ltd. |
Disease Prevention and Vaccination Prior to Thymic Reactivation
|
|
KR20080083220A
(ko)
|
2004-04-07 |
2008-09-16 |
노파르티스 아게 |
Ｉａｐ 억제제
|
|
GB0512324D0
(en)
|
2005-06-16 |
2005-07-27 |
Novartis Ag |
Organic compounds
|
|
CN101863971A
(zh)
*
|
2004-06-25 |
2010-10-20 |
武田药品工业株式会社 |
转移素衍生物及其用途
|
|
PL1809329T3
(pl)
|
2004-09-17 |
2012-08-31 |
Durect Corp |
Kompozycja znieczulająca zawierająca saib o przedłużonym uwalnianiu do stosowania miejscowego
|
|
GB0425854D0
(en)
*
|
2004-11-25 |
2004-12-29 |
Astrazeneca Ab |
Therapeutic treatment
|
|
AR054425A1
(es)
|
2005-01-21 |
2007-06-27 |
Astex Therapeutics Ltd |
Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico.
|
|
US8404718B2
(en)
|
2005-01-21 |
2013-03-26 |
Astex Therapeutics Limited |
Combinations of pyrazole kinase inhibitors
|
|
MX2007008781A
(es)
|
2005-01-21 |
2007-09-11 |
Astex Therapeutics Ltd |
Compuestos farmaceuticos.
|
|
DE602006011099D1
(de)
|
2005-05-03 |
2010-01-28 |
Novetide Ltd |
Verfahren zur herstellung von peptidderivaten
|
|
GB0510390D0
(en)
|
2005-05-20 |
2005-06-29 |
Novartis Ag |
Organic compounds
|
|
US20070027105A1
(en)
|
2005-07-26 |
2007-02-01 |
Alza Corporation |
Peroxide removal from drug delivery vehicle
|
|
AU2006294850A1
(en)
|
2005-09-27 |
2007-04-05 |
Novartis Ag |
Carboxyamine compounds and their use in the treatment of HDAC dependent diseases
|
|
GB0605120D0
(en)
|
2006-03-14 |
2006-04-26 |
Novartis Ag |
Organic Compounds
|
|
JP2009536180A
(ja)
|
2006-05-09 |
2009-10-08 |
ノバルティス アクチエンゲゼルシャフト |
鉄キレート剤と抗新生物剤を含む組合せ剤およびそれらの使用
|
|
CA2664378A1
(en)
|
2006-09-29 |
2008-04-03 |
Novartis Ag |
Pyrazolopyrimidines as pi3k lipid kinase inhibitors
|
|
JP5528806B2
(ja)
|
2006-10-12 |
2014-06-25 |
アステックス、セラピューティックス、リミテッド |
複合薬剤
|
|
JP5528807B2
(ja)
|
2006-10-12 |
2014-06-25 |
アステックス、セラピューティックス、リミテッド |
複合薬剤
|
|
US8337883B2
(en)
|
2006-11-03 |
2012-12-25 |
Durect Corporation |
Transdermal delivery systems
|
|
RU2009134223A
(ru)
|
2007-02-15 |
2011-03-20 |
Новартис АГ (CH) |
Комбинация lbh589 с другими терапевтическими средствами, предназначенная для лечения рака
|
|
WO2009088414A2
(en)
|
2007-12-06 |
2009-07-16 |
Durect Corporation |
Oral pharmaceutical dosage forms
|
|
EA020114B1
(ru)
|
2008-03-24 |
2014-08-29 |
Новартис Аг |
Производные арилсульфонамида в качестве ингибиторов матриксной металлопротеазы
|
|
EP2628726A1
(en)
|
2008-03-26 |
2013-08-21 |
Novartis AG |
Hydroxamate-based inhibitors of deacetylases b
|
|
US20100260844A1
(en)
|
2008-11-03 |
2010-10-14 |
Scicinski Jan J |
Oral pharmaceutical dosage forms
|
|
ES2621141T3
(es)
*
|
2008-11-28 |
2017-07-03 |
Novartis Ag |
Combinación farmacéutica que comprende un inhibidor de Hsp 90 y un inhibidor de mTOR
|
|
WO2010083617A1
(en)
|
2009-01-21 |
2010-07-29 |
Oncalis Ag |
Pyrazolopyrimidines as protein kinase inhibitors
|
|
TW201031406A
(en)
|
2009-01-29 |
2010-09-01 |
Novartis Ag |
Substituted benzimidazoles for the treatment of astrocytomas
|
|
KR101360725B1
(ko)
|
2009-06-26 |
2014-02-07 |
노파르티스 아게 |
Ｃｙｐ17의 억제제로서의 1,3-이치환된 이미다졸리딘-2-온 유도체
|
|
US8389526B2
(en)
|
2009-08-07 |
2013-03-05 |
Novartis Ag |
3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
|
|
CA2770873A1
(en)
|
2009-08-12 |
2011-02-17 |
Novartis Ag |
Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation
|
|
EP2467383A1
(en)
|
2009-08-20 |
2012-06-27 |
Novartis AG |
Heterocyclic oxime compounds
|
|
US20120149661A1
(en)
|
2009-08-26 |
2012-06-14 |
Novartis Ag |
Tetra-substituted heteroaryl compounds and their use as mdm2 and/or mdm4 modulators
|
|
EP2475668A1
(en)
|
2009-09-10 |
2012-07-18 |
Novartis AG |
Ether derivatives of bicyclic heteroaryls
|
|
MY156209A
(en)
|
2009-11-04 |
2016-01-29 |
Novartis Ag |
Heterocyclic sulfonamide derivatives useful mek inhibitors
|
|
US20120289501A1
(en)
|
2009-11-25 |
2012-11-15 |
Novartis Ag |
Benzene-fused 6-membered oxygen-containing heterocyclic derivatives of bicyclic heteroaryls
|
|
EP2509964B1
(en)
|
2009-12-08 |
2014-04-30 |
Novartis AG |
Heterocyclic sulfonamide derivatives
|
|
CU24130B1
(es)
|
2009-12-22 |
2015-09-29 |
Novartis Ag |
Isoquinolinonas y quinazolinonas sustituidas
|
|
US8440693B2
(en)
|
2009-12-22 |
2013-05-14 |
Novartis Ag |
Substituted isoquinolinones and quinazolinones
|
|
BR112012032189B1
(pt)
|
2010-06-16 |
2020-11-03 |
Endorecherche, Inc |
usos de um agonista ou antagonista de lhrh em associação com um modulador de receptor de estrogênio seletivo e com um precursor de esteróide sexual para a preparação de uma medicamento para o tratamento ou prevenção de doenças relacionadas com estrogênio e kits
|
|
JP2013528635A
(ja)
|
2010-06-17 |
2013-07-11 |
ノバルティス アーゲー |
ビフェニル置換１，３−ジヒドロ−ベンゾイミダゾール−２−イリデンアミン誘導体
|
|
US20130085161A1
(en)
|
2010-06-17 |
2013-04-04 |
Novartis Ag |
Piperidinyl substituted 1,3-dihydro-benzoimidazol-2-ylideneamine derivatives
|
|
UA112517C2
(uk)
|
2010-07-06 |
2016-09-26 |
Новартіс Аг |
Тетрагідропіридопіримідинові похідні
|
|
US8946260B2
(en)
|
2010-09-16 |
2015-02-03 |
Novartis Ag |
17α-hydroxylase/C17,20-lyase inhibitors
|
|
EP2673277A1
(en)
|
2011-02-10 |
2013-12-18 |
Novartis AG |
[1, 2, 4]triazolo [4, 3 -b]pyridazine compounds as inhibitors of the c-met tyrosine kinase
|
|
EP2683722A1
(en)
|
2011-03-08 |
2014-01-15 |
Novartis AG |
Fluorophenyl bicyclic heteroaryl compounds
|
|
MX359399B
(es)
|
2011-04-28 |
2018-09-27 |
Novartis Ag |
Inhibidores de 17alfa-hidroxilasa/c17-20-liasa.
|
|
KR20210094672A
(ko)
|
2011-05-16 |
2021-07-29 |
젠자임 코포레이션 |
Ｃｘｃｒ４ 길항제의 용도
|
|
MX2013014398A
(es)
|
2011-06-09 |
2014-03-21 |
Novartis Ag |
Derivados de sulfonamida heterociclicos.
|
|
EP2721008B1
(en)
|
2011-06-20 |
2015-04-29 |
Novartis AG |
Hydroxy substituted isoquinolinone derivatives as p53 (mdm2 or mdm4) inhibitors
|
|
EP2721007B1
(en)
|
2011-06-20 |
2015-04-29 |
Novartis AG |
Cyclohexyl isoquinolinone compounds
|
|
WO2013001445A1
(en)
|
2011-06-27 |
2013-01-03 |
Novartis Ag |
Solid forms and salts of tetrahydro-pyrido-pyrimidine derivatives
|
|
ES2691650T3
(es)
|
2011-09-15 |
2018-11-28 |
Novartis Ag |
3-(quinolin-6-il-tio)-[1,2,4]-triazolo-[4,3-a]-piridinas 6-sustituidas como inhibidores de tirosina quinasa c-Met
|
|
WO2013080141A1
(en)
|
2011-11-29 |
2013-06-06 |
Novartis Ag |
Pyrazolopyrrolidine compounds
|
|
PL2794600T3
(pl)
|
2011-12-22 |
2018-06-29 |
Novartis Ag |
Pochodne 2,3-dihydro-benzo[1,4]oksazyny i powiązane związki jako inhibitory kinazy fosfoinozytydu-3 (PI3K) do leczenia np. reumatoidalnego zapalenia stawów
|
|
EP2794594A1
(en)
|
2011-12-22 |
2014-10-29 |
Novartis AG |
Quinoline derivatives
|
|
MX2014007731A
(es)
|
2011-12-23 |
2015-01-12 |
Novartis Ag |
Compuestos para inhibir la interaccion de bcl2 con los componentes de enlace.
|
|
EA201491259A1
(ru)
|
2011-12-23 |
2014-11-28 |
Новартис Аг |
Соединения и композиции для ингибирования взаимодействия bcl2 с партнерами связывания
|
|
CA2859869A1
(en)
|
2011-12-23 |
2013-06-27 |
Novartis Ag |
Compounds for inhibiting the interaction of bcl2 with binding partners
|
|
US9126980B2
(en)
|
2011-12-23 |
2015-09-08 |
Novartis Ag |
Compounds for inhibiting the interaction of BCL2 with binding partners
|
|
BR112014015308A2
(pt)
|
2011-12-23 |
2017-06-13 |
Novartis Ag |
compostos para inibição da interação de bcl2 com contrapartes de ligação
|
|
JO3357B1
(ar)
|
2012-01-26 |
2019-03-13 |
Novartis Ag |
مركبات إيميدازوبيروليدينون
|
|
US20130310387A1
(en)
|
2012-05-16 |
2013-11-21 |
Novartis Ag |
Monocyclic Heteroaryl Cycloalkyldiamine Derivatives
|
|
JP6171003B2
(ja)
|
2012-05-24 |
2017-07-26 |
ノバルティス アーゲー |
ピロロピロリジノン化合物
|
|
JP6427097B2
(ja)
|
2012-06-15 |
2018-11-21 |
ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． |
癌を処置するための組成物および該組成物を製造するための方法
|
|
CN104520297B
(zh)
|
2012-08-13 |
2016-08-24 |
瑞士诺华动物保健有限公司 |
作为肾酪氨酸激酶抑制剂的双环杂芳基环烷基二胺衍生物
|
|
NZ706635A
(en)
|
2012-10-02 |
2018-08-31 |
Gilead Sciences Inc |
Inhibitors of histone demethylases
|
|
TW201422625A
(zh)
|
2012-11-26 |
2014-06-16 |
Novartis Ag |
二氫－吡啶并－□衍生物之固體形式
|
|
US9403827B2
(en)
|
2013-01-22 |
2016-08-02 |
Novartis Ag |
Substituted purinone compounds
|
|
EP2948453B1
(en)
|
2013-01-22 |
2017-08-02 |
Novartis AG |
Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the p53/mdm2 interaction
|
|
WO2014128612A1
(en)
|
2013-02-20 |
2014-08-28 |
Novartis Ag |
Quinazolin-4-one derivatives
|
|
SG11201506717UA
(en)
|
2013-02-27 |
2015-09-29 |
Epitherapeutics Aps |
Inhibitors of histone demethylases
|
|
CA2905131A1
(en)
|
2013-03-15 |
2014-09-18 |
Durect Corporation |
Compositions with a rheological modifier to reduce dissolution variability
|
|
US20150018376A1
(en)
|
2013-05-17 |
2015-01-15 |
Novartis Ag |
Pyrimidin-4-yl)oxy)-1h-indole-1-carboxamide derivatives and use thereof
|
|
UY35675A
(es)
|
2013-07-24 |
2015-02-27 |
Novartis Ag |
Derivados sustituidos de quinazolin-4-ona
|
|
WO2015022664A1
(en)
|
2013-08-14 |
2015-02-19 |
Novartis Ag |
Compounds and compositions as inhibitors of mek
|
|
US9227969B2
(en)
|
2013-08-14 |
2016-01-05 |
Novartis Ag |
Compounds and compositions as inhibitors of MEK
|
|
WO2015022663A1
(en)
|
2013-08-14 |
2015-02-19 |
Novartis Ag |
Compounds and compositions as inhibitors of mek
|
|
BR112016003229A8
(pt)
|
2013-09-22 |
2020-02-04 |
Calitor Sciences Llc |
composto, composição farmacêutica, e, uso de um composto ou de uma composição farmacêutica
|
|
KR20160101027A
(ko)
|
2014-01-15 |
2016-08-24 |
노파르티스 아게 |
제약 조합물
|
|
WO2015148867A1
(en)
|
2014-03-28 |
2015-10-01 |
Calitor Sciences, Llc |
Substituted heteroaryl compounds and methods of use
|
|
EP3126345A1
(en)
|
2014-03-31 |
2017-02-08 |
Gilead Sciences, Inc. |
Inhibitors of histone demethylases
|
|
WO2015153345A1
(en)
|
2014-04-03 |
2015-10-08 |
Invictus Oncology Pvt. Ltd. |
Supramolecular combinatorial therapeutics
|
|
WO2016033169A1
(en)
|
2014-08-27 |
2016-03-03 |
Epitherapeutics Aps |
Compounds and methods for inhibiting histone demethylases
|
|
WO2017044434A1
(en)
|
2015-09-11 |
2017-03-16 |
Sunshine Lake Pharma Co., Ltd. |
Substituted heteroaryl compounds and methods of use
|
|
JP7254076B2
(ja)
|
2017-11-19 |
2023-04-07 |
サンシャイン・レイク・ファーマ・カンパニー・リミテッド |
置換ヘテロアリール化合物及び使用方法
|
|
JP7021356B2
(ja)
|
2017-12-21 |
2022-02-16 |
ヘフェイ インスティテューツ オブ フィジカル サイエンス， チャイニーズ アカデミー オブ サイエンシーズ |
ピリミジン誘導体系キナーゼ阻害剤類
|
|
WO2019143874A1
(en)
|
2018-01-20 |
2019-07-25 |
Sunshine Lake Pharma Co., Ltd. |
Substituted aminopyrimidine compounds and methods of use
|
|
CA3155594A1
(en)
*
|
2019-09-26 |
2021-04-01 |
S.I.S. Shulov Innovative Science Ltd. |
Topical anti-aging compositions comprising a tetrapeptide
|
|
EP4058465A1
(en)
|
2019-11-14 |
2022-09-21 |
Cohbar Inc. |
Cxcr4 antagonist peptides
|
|
KR20220140711A
(ko)
|
2020-01-13 |
2022-10-18 |
듀렉트 코퍼레이션 |
불순물이 감소된 지속 방출 약물 전달 시스템 및 관련 방법
|